+357.4%
SOXL vs MRNA
+511.3%
-153.9%
-69.4%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | +9.9% | -2.2% | +12.1% | +9.9% |
| 7D | +5.3% | +5.5% | -0.1% | +5.1% |
| 30D | -11.2% | +158.7% | -169.9% | -20.4% |
| 3M | -55.4% | +182.1% | -237.5% | -63.5% |
| 6M | +107.1% | +151.8% | -44.7% | +77.4% |
| YTD | +179.0% | +393.6% | -214.5% | +78.4% |
| 1Y | +357.4% | +499.5% | -142.1% | +174.0% |
| All | +357.4% | +511.3% | -153.9% | +174.0% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling